Researcher.Life Logo

Diabetes Technology and Therapeutics : Impact Factor & More

eISSN: 1557-8593pISSN: 1520-9156

Key Metrics

CiteScore
10.3
Eigenfactor
0.005 - 0.01
H-Index
97
Impact Factor
5 - 10
SJR
Q1Endocrinology
SNIP
1.97
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Diabetes Technology and Therapeutics

Diabetes Technology and Therapeutics Journal Specifications

Overview
Publisher MARY ANN LIEBERT, INC
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1999
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Diabetes Technology and Therapeutics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Diabetes Technology and Therapeutics

All-Cause Mortality and Health Care Resource Utilization in Patients with Type 1 Diabetes Treated with Glucagon-like Peptide 1 Receptor Agonists/Glucose-Dependent Insulinotropic Polypeptide.
  • 22 Dec 2025
  • Diabetes technology & therapeutics
Antigen-Specific Chimeric Antigen Receptor-T Regulatory Cells Home to Human Islets, Suppress Cytotoxic T Lymphocytes and Reverse Type 1 Diabetes.
  • 22 Dec 2025
  • Diabetes technology & therapeutics
Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.
  • 22 Dec 2025
  • Diabetes technology & therapeutics
Letter: Response to: "Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia".
  • 22 Dec 2025
  • Diabetes technology & therapeutics
An Exploratory Analysis of Continuous Glucose Monitoring Metrics in Relation to Prediabetes in Youths with Obesity.
  • 22 Dec 2025
  • Diabetes technology & therapeutics
Twenty-Five Hours of Fasting with Automated Insulin Delivery in Youth with Type 1 Diabetes.
  • 22 Dec 2025
  • Diabetes technology & therapeutics
All-Cause Mortality and Health Care Resource Utilization in Patients with Type 1 Diabetes Treated with Glucagon-like Peptide 1 Receptor Agonists/Glucose-Dependent Insulinotropic Polypeptide.
  • 22 Dec 2025
  • Diabetes technology & therapeutics
Antigen-Specific Chimeric Antigen Receptor-T Regulatory Cells Home to Human Islets, Suppress Cytotoxic T Lymphocytes and Reverse Type 1 Diabetes.
  • 22 Dec 2025
  • Diabetes technology & therapeutics
Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.
  • 22 Dec 2025
  • Diabetes technology & therapeutics
Letter: Response to: "Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia".
  • 22 Dec 2025
  • Diabetes technology & therapeutics
An Exploratory Analysis of Continuous Glucose Monitoring Metrics in Relation to Prediabetes in Youths with Obesity.
  • 22 Dec 2025
  • Diabetes technology & therapeutics
Twenty-Five Hours of Fasting with Automated Insulin Delivery in Youth with Type 1 Diabetes.
  • 22 Dec 2025
  • Diabetes technology & therapeutics

FAQs on Diabetes Technology and Therapeutics